FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to the use of pertuzumab for the treatment of HER2-positive oncological disease. Pertuzumab is injected subcutaneously in a combination with subcutaneously injected trastuzumab.
EFFECT: invention allows for effective treatment of HER2-positive oncological disease.
16 cl, 31 dwg, 6 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2806049C2 |
| VERSIONS OF PERTUZUMAB AND THEIR ANALYTICAL CHARACTERISTICS | 2014 |
|
RU2737727C2 |
| BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 | 2014 |
|
RU2737882C2 |
| BISPECIFIC ANTIGEN-BINDING POLYPEPTIDES | 2015 |
|
RU2723940C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| PHARMACEUTICAL COMPOSITION, INCLUDING A PH20 VARIANT OF HUMAN HYALURONIDASE, AND A MEDICINAL PRODUCT FOR SUBCUTANEOUS ADMINISTRATION | 2020 |
|
RU2810952C2 |
| METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR TREATING BILE DUCT CANCER | 2019 |
|
RU2819802C2 |
| COMBINATION THERAPY FOR CANCER TREATMENT USING RECOMBINANT MVA AND ANTIBODIES INTRODUCED INTRAVENOUSLY | 2018 |
|
RU2795103C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
